Amphilimus- vs Zotarolimus-Eluting Stents in Patients With Diabetes and Coronary Artery Disease
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
European Heart Journal
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Amphilimus- versus zotarolimus-eluting stents in patients with diabetes mellitus and coronary artery disease (SUGAR trial)
Eur Heart J 2021 Nov 04;[EPub Ahead of Print], R Romaguera, P Salinas, J Gomez-Lara, S Brugaletta, A Gómez-Menchero, MA Romero, S García-Blas, R Ocaranza, P Bordes, MJ Kockar, N Salvatella, VA Jiménez-Díaz, M Alameda, R Trillo, DH Lee, P Martín, M López-Benito, A Freites, V Pascual-Tejerino, F Hernández-Hernández, B García Del Blanco, M Mohandes, F Bosa, E Pinar, G Roura, J Comin-Colet, A Fernández-Ortiz, C Macaya, X Rossello, M Sabate, SJ Pocock, JA Gómez-HospitalFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.